Teriflunomide

CAS : 163451-81-8

Ref. 3D-J-010046

Informations sur le produit

• Nom: Teriflunomide
• Synonymes: A 771726 N-(4-Trifluoromethylphenyl)-2-cyano-3-hydroxycrotoamide, (2Z)-2-(hydroxy{[4-(trifluoromethyl)phenyl]amino}methylidene)-3-oxobutanenitrile, (2Z)-2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide, (Z)-2-Cyano-alpha'alpha'alpha-trifluoro-3-hydroxy-p-crotonotoluidide, 2-Butenamide, 2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-, 2-Butenamide, 2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-, (2Z)-, 2-Butenamide, 2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-, (Z)-, 2-Cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-butenamide, A 1726, A 77-1726, A 771726, A771726, Active metabolite of leflunomide, Aubagio, Femorix, Flucyamide, Hmr 1726, Malononitrilamide, N-(4-Trifluoromethylphenyl)-2-cyano-2-hydroxycrotonamide, Su 20, Teriflunomide [INN], Unii-1C058Ikg3B

Description

Teriflunomide is a drug that has been clinically proven for the treatment of multiple sclerosis. It is a prodrug that is converted to its active form, teriflunomide-phosphate, in vivo. Teriflunomide inhibits the activity of matrix metalloproteinases by blocking Ca2+ channels and inhibiting Ca2+ influx into the cytosol. This blocks the degradation of extracellular matrix proteins and reduces inflammation, which may lead to long-term efficacy in autoimmune diseases such as multiple sclerosis. Teriflunomide also decreases T-cell proliferation by inhibiting integrin receptors on T cells and monoclonal antibody production.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 270.21 g/mol
• Formule: C₁₂H₉F₃N₂O₂
• Degré de pureté: Min. 98 Area-%